Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZFV3E)

Drug Name
Remogli ozin-etabonate Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMZFV3E
VARIDT Drug ID
DR01139

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Sodium/glucose cotransporter 2 (SLC5A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SaxaDapa FDC DMAPRWV Diabetic complication 5A2Y Phase 3 [3]
RG7201 DMJRFYB Type-2 diabetes 5A11 Phase 3 [4]
Remogliflozin etabonate DMW4YK1 Type-1/2 diabetes 5A10-5A11 Phase 2 [5]
Ponalrestat DM04ZUW Gout FA25 Discontinued in Phase 3 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/glucose cotransporter 2 (SLC5A4) TTN7Y4P SC5A4_HUMAN Modulator [2]

References

1 Clinical pipeline report, company report or official report of Bhv pharma.
2 Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
3 Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
4 Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).